Evidence map›Paper›PMID 34249427›Full record

ArticleAmerican journal of cancer research2021

Identification and prognostic analysis of the cetuximab resistance-related gene

Ning Zhu, Xuefeng Fang, Dan Li, Mengyuan Yang, Lizhen Zhu, Liping Zhong, Shanshan Weng, Juan Wang, Ying Yuan

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. A study of gene variation in All-Journal of gastrointestinal oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ning ZhuDepartment of Medical Oncology, Key Labaratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China.
Xuefeng FangDepartment of Medical Oncology, Key Labaratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China.
Dan LiDepartment of Medical Oncology, Key Labaratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China.
Mengyuan YangDepartment of Medical Oncology, Key Labaratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China.
Lizhen ZhuDepartment of Medical Oncology, Key Labaratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China.
Liping ZhongDepartment of Medical Oncology, Key Labaratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China.
Shanshan WengDepartment of Medical Oncology, Key Labaratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China.
Juan WangDepartment of Medical Oncology, Key Labaratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China.
Ying YuanDepartment of Medical Oncology, Key Labaratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China.
Zhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The survival of patients with

Indexed as

cetuximabColorectal cancerresistanceREV1whole-exome sequencing

Identifiers

PMID34249427
PMCPMC8263679
OpenAlexW3179512777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.